Archives: Agenda

• Who needs to be risky? – vendor management team
• What tools are needed to manage risks?
• What qualification activities are needed? Less audits?
• How much oversight and management?

• How strategic partnerships can positively impact diversity in clinical trials
• Leveraging these partnerships to enhance community engagement
• Planning for diversity at the onset

Interactive roundtable sessions offer a unique opportunity to come together with your peers to share best practice and develop solutions to critical challenges facing the industry as a whole. Hosted by industry experts and each focused on a single issue, roundtables are an exciting, interactive way to build your personal network and learn from the experience and expertise of others.

Each roundtable session lasts for 30 minutes, and delegates may attend up to 2 roundtables.

RT1 – Collaboration on trial design and execution to ensure study success
Stacey Curelop, Director of Clinical Operations, Mycovia Pharmaceuticals

RT2 – Beyond Compliance: Fostering a culture of inclusion in Clinical Trials
Bianca Green, Senior Manager, Diversity Equity & Inclusion in Clinical Trials, Takeda

RT3 – Strategies for Smaller Pharma & Biotech’s to Overcome Financial and Resource Challenges

Ros Cheetham, Vice President Clinical Operations, MacroGenics

• • Exploring how patients could, and should, be influencing decisions and the R&D process before study start-up.
  • How to optimize collaboration with patient advocacy organizations
  • Discussing recipes for success and the challenges which are still visible.
  • Real-life examples: when has it worked, when hasn’t it and why?

• Best and worst business development practices for reaching sponsors
• Best and worst practices for sponsors working with BD in seeking quotes and outsourced work
• Understanding and respecting each party’s requirements and pressures

The landscape of clinical trials is undergoing a transformative shift as digital technologies continue to permeate every aspect of the healthcare industry. One potential transformation could be the replacement of traditional paper-based relabelling in clinical trials with digital display labels. The integration of digital display labels into clinical trials represents a significant leap forward in the industry. As this technology matures and becomes more widely adopted, it could impact the way clinical trials are conducted and managed especially in the areas of remote monitoring, adaptive trials, and patient engagement. In this session, we will explore the challenges associated with traditional relabelling processes in clinical trials, the advantages of adopting digital display labels, and the potential impact on the future of healthcare research.